Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05BMC
|
|||
| Former ID |
DIB013064
|
|||
| Drug Name |
GW-42004
|
|||
| Synonyms |
CB1/CB2 receptor antagonist (oral/capsule, obesity/type 2 diabetes/dyslipidemia), GW Pharmaceuticals
Click to Show/Hide
|
|||
| Indication | Lipid metabolism disorder [ICD-11: 5C52.Z] | Phase 2 | [1] | |
| Company |
GW Pharmaceuticals plc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | Modulator | [2] |
| Cannabinoid receptor 2 (CB2) | Target Info | Modulator | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Rap1 signaling pathway | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| BDNF signaling pathway | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036909) | |||
| REF 2 | Company report (Gwpharm) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.